[1]
|
R. B. Raffa and E. Friderichs, “The Basic Science Aspect of Tramadol Hydrochloride,” Pain Reviews, Vol. 3, 1996, pp. 249-271.
|
[2]
|
T. Itoh, “Control of Non-Malignant Chronic Pain Conditions in Japan and the Possible Future Role of Tramadol,” European Journal of Pain, Vol. 5, Suppl. A, 2001, pp. 87-89.
|
[3]
|
S. Saeki, “Indication and Usage of Opioids Except Morphine for Chronic Non-Malignant Intractable Pain,” Masui, Japanese Journal of Anesthesiology, Vol. 57, No. 11, 2008, pp. 1351-1358.
|
[4]
|
T. Yanagita, “Drug Dependence Potential of 1-(M-meth- oxy-phenyl)-2-dimethylaminomethyl)-cyclohexan-1-ol- hydrochloride (Tramadol) Tested in Monkeys,” Arzneim-it-telforschung, Vol. 28, No. 1a, 1978, pp. 158-163.
|
[5]
|
K. Mimami, “Recent Evidences in the Pharmacological Mechanisms of the Tramadol,” Masui, Japanese Journal of Anesthesiology, Vol. 54, No. 11, 2005, pp. 1224-1233.
|
[6]
|
C. Li, S. Q. Chen, B. X. Chen, W. Q. Huang and K. X. Liu, “The Antinociceptive Effect of In-trathecal Tramadol in Rats: The Role of Alpha 2-Adrenoceptors in the Spinal Cord,” Journal of Anesthesia, Vol. 25, No. 2, 2012, pp. 230-235.
|
[7]
|
K. Minami, T. Yokoyama, J. Ogata and Y. Uezono, “The Tramadol Metabolite O-Desmethyl Tramadol Inhibits Substance P-Receptor Functions Expressed in Xenopus Oocytes,” Journal of Pharmacological Sciences, Vol. 115, No. 3, 2011, pp. 421-424. doi:10.1254/jphs.10313SC
|
[8]
|
Y. Yamazoe and K. Nagata, “Genetic Polymorphism in Human Drug Metabolism,” Nihon Yakurigaku Zasshi, Vol. 101, No. 2, 1993, pp. 69-77.
doi:10.1254/fpj.101.2_69
|
[9]
|
T. Yokoi and T. Kamataki, “Genetic Polymorphism of Drug Metabolizing Enzymes: New Mutations in CYP2D6 and CYP2A6 Genes in Japa-nese,” Nihon Yakurigaku Zasshi, Vol. 112, No. 1, 1998, pp. 5-14.
doi:10.1254/fpj.112.5
|
[10]
|
M. Chida, T. Yokoi, Y. Kosaka, K. Chiba, H. Nakamura, T. Ishizaki, J. Yokota, M. Kinoshita, K. Sato, M. Inaba, Y. Aoki, F. J. Gonzalez and T. Kamataki, “Genetic Polymorphism of CYP2D6 in the Japanese Population,” Pharmacogenetics, Vol. 9, No. 5, 1999, pp. 601-605.
|
[11]
|
Y. Mitsunaga, T. Kubota, A. Ishiguro, Y. Yamada, H. Sasaki, K. Chiba and T. Iga, “Frequent Occurrence of CYP2D6*10 Duplication Allele in a Japanese Population,” Mutation Research, Vol. 505, No. 1-2, 2002, pp. 83-85. doi:10.1016/S0027-5107(02)00122-7
|
[12]
|
M. Kitada, “Genetic Polymorphism of Cytochrome P450 Enzymes in Asian Populations: Focus on CYP2D6,” International Journal Clinical Pharmacology Research, Vol. 23, No. 1, 2003, pp. 31-35.
|
[13]
|
T. Mizutani, “PM Frequencies of Major CYPs in Asians and Caucasians,” Drug Metabol-ism Reviews, Vol. 35, No. 2-3, 2003, pp. 99-106.
doi:10.1081/DMR-120023681
|
[14]
|
B. Schmid, J. Bircher, R. Preisig and A. Kupfer, “Poly- morphic Dextromethor-phan Metabolism: Co-Segregation of Oxidative O-Demethylation with Debrisoquin Hydroxylation,” Clinical Pharmacology & Therapeutics, Vol. 38, No. 6, 1985, pp. 618-624.
doi:10.1038/clpt.1985.235
|
[15]
|
N. Nagai, T. Kawakubo, F. Kaneko, M. Ishii, R. Shino- hara, Y. Saito, H. Shima-mura, A. Ohnishi and H. Ogata, “Pharmacokinetics and Polymorphic Oxidation of Dextromethorphan in a Japa-nese Population,” Biopharmaceutics & Drug Disposition, Vol. 17, No. 5, 1996, pp. 421- 433.
doi:10.1002/(SICI)1099-081X(199607)17:5<421::AID-BDD421>3.0.CO;2-9
|
[16]
|
Y. Ikenaga, T. Fukuda, K. Fu-kuda, Y. Nishida, M. Naohara, H. Maune and J. Azuma, “The Frequency of Candidate Alleles for CYP2D6 Geno-typing in the Japanese Population with an Additional Respect to the –1584C to G Substitution,” Drug Metabolism and Pharmacokinetics, Vol. 20, No. 2, 2005, pp. 113-116.
doi:10.2133/dmpk.20.113
|
[17]
|
A. Ebisawa, M. Hiratsuka, K. Sakuyama, Y. Konno, T. Sasaki and M. Mizugaki, “Two Novel Single Nucleotide Polymorphisms (SNPs) of the CYP2D6 Gene in Japanese Individuals,” Drug Meta-bolism and Pharmacokinetics, Vol. 20, No. 4, 2005, pp. 294-299.
doi:10.2133/dmpk.20.294
|
[18]
|
H. Yokota, S. Tamura, H. Furuya, S. Kimura, M. Watanabe, I. Kanazawa, I. Kondo and F. J. Gonzalez, “Evidence for a New Variant CYP2D6 Allele CYP2D6J in a Japanese Population Associated with Lower in Vivo Rates of Sparteine Metabolism,” Pharmacogenetics, Vol. 3, No. 5, 1993, pp. 256-263.
doi:10.1097/00008571-199310000-00005
|
[19]
|
M. L. Dahl, Q. Y. Yue, H. K. Roh, I. Johansson, J. Sawe, F. Sjoqvist and L. Bertilsson, “Genetic Analysis of the CYP2D Locus in Relation to Debrisoquine Hydroxylation Capacity in Korean, Japanese and Chinese Subjects,” Pharmacogenetics, Vol. 5, No. 3, 1995, pp. 159-164.
doi:10.1097/00008571-199506000-00004
|
[20]
|
A. Ishiguro, T. Kubota, H. Sasaki, Y. Yamada and T. Iga, “Common Mutant Alleles of CYP2D6 Causing the Defect of CYP2D6 Enzyme Activity in a Japanese Population,” British Journal of Clinical Pharmacology, Vol. 55, No. 4, 2003, pp. 414-415.
doi:10.1046/j.1365-2125.2003.01782.x
|
[21]
|
K. Sakuyama, T. Sasaki, S. Ujiie, K. Obata, M. Mizugaki, M. Ishi-kawa and M. Hiratsuka, “Functional Characterization of 17 CYP2D6 Allelic Variants (CYP2 D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57),” Drug Metabolism and Disposition, Vol. 36, No. 12, 2008, pp. 2460-2467. doi:10.1124/dmd.108.023242
|
[22]
|
M. Matsunaga, H. Yamazaki, K. Kiyotani, S. Iwano, J. Saruwatari, K. Nakagawa, A. Soyama, S. Ozawa, J. Sawada, E. Kashiyama, M. Kinoshita and T. Kamataki, “Two Novel CYP2D6*10 Haplotypes as Possible Causes of a Poor Metabolic Phe-notype in Japanese,” Drug Metabolism and Disposition, Vol. 37, No. 4, 2009, pp. 699-701. doi:10.1124/dmd.108.026096
|
[23]
|
I. Johansson, M. Oscarson, Q. Y. Yue, L. Bertilsson, F. Sjoqvist and M. Ingelman-Sundberg, “Genetic Analysis of the Chinese Cy-tochrome P4502D Locus: Characterization of Variant CYP2D6 Genes Present in Subjects with Diminished Ca-pacity for Debrisoquine Hydroxylation,” Molecular Pharmacology, Vol. 46, No. 3, 1994, pp. 452- 459.
|
[24]
|
T. Tateishi, M. Chida, N. Ariyoshi, Y. Mizorogi, T. Kamataki and S. Kobayashi, “Analysis of the CYP2D6 Gene in Relation to Dextromethorphan O-Demethylation Capacity in a Japanese Population,” Clinical Pharmacology & Therapeutics, Vol. 65, No. 5, 1999, pp. 570-575.
doi:10.1016/S0009-9236(99)70077-9
|
[25]
|
T. Kubota, Y. Yamaura, N. Ohkawa, H. Hara and K. Chiba, “Frequencies of CYP2D6 Mutant Alleles in a Normal Japanese Population and Metabolic Activity of Dextromethorphan O-Demethylation in Different CYP2D6 Genotypes,” British Journal of Clinical Pharmacology, Vol. 50, No. 1, 2000, pp. 31-34.
doi:10.1046/j.1365-2125.2000.00209.x
|
[26]
|
S. H. Gan, R. Ismail, W. A. Wan Adnan and Z. Wan, “Correlation of Tramadol Pharmacokinetics and CYP 2D6*10 Genotype in Malaysian Subjects,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 30, No. 2, 2002, pp. 189-195.
doi:10.1016/S0731-7085(02)00214-5
|
[27]
|
M. Kitahara, K. Kojima, M. Hanada, Y. Kuriyama and A. Ohmura, “Effectiveness of Oral Tramadol Hydrochloride for Chronic Non-Malignant Pain,” Masui, Japanese Journal of Anesthesiology, Vol. 58, No. 8, 2009, pp. 971-975.
|
[28]
|
G. Wang, H. Zhang, F. He and X. Fang, “Effect of the CYP2D6*10 C188T Polymorphism on Postoperative Tramadol Analgesia in a Chinese Popula-tion,” European Journal of Clinical Pharmacology, Vol. 62, No. 11, 2006, pp. 927-931.doi:10.1007/s00228-006-0191-2
|
[29]
|
K. Ijichi, K. Nijima, T. Iwagaki, J. Irie and Y. Uratsuji, “A Rando-mized Double-Blind Comparison of Epidural versus Intravenous Tramadol Infusion for Postoperative Analgesia,” Masui, Japanese Journal of Anesthesiology, Vol. 54, No. 6, 2005, pp. 615-621.
|
[30]
|
Y. Kaneda, I. Kawamura, A. Fujii and T. Ohmori, “Serotonin Syndrome—‘Potential’ Role of the CYP2D6 Genetic Polymorphism in Asians,” International Journal of Neuropsychopharmacology, Vol. 5, No. 1, 2002, pp. 105-106. doi:10.1017/S1461145701002723
|